Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors

First‐in‐Human Phase I Study of Envafolimab, a Novel Subcutaneous Single‐Domain Anti‐PD‐L1 Antibody, in Patients with Advanced Solid Tumors

(2021) Kyriakos P. Papadopoulos et al.   ONCOLOGIST

Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients

(2019) Bixia Tang et al.   Journal of Hematology & Oncology

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura

(2019) Marie Scully et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial

(2019) Yuankai Shi et al.   Lancet Haematology

Phase I safety and pharmacokinetic study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in Japanese patients with advanced solid tumors.

(2019) Toshio Shimizu et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in patients with advanced solid tumors in China.

(2019) Jian-Ming Xu et al.   JOURNAL OF CLINICAL ONCOLOGY

Structured literature review (SLR) and meta-analyses of the prevalence of microsatellite instability high (MSI-H) and deficient mismatch repair (dMMR) in gastric, colorectal, and esophageal cancers.

(2019) Mayur Amonkar et al.   JOURNAL OF CLINICAL ONCOLOGY

Nanobody approval gives domain antibodies a boost

(2019) Chris Morrison   NATURE REVIEWS DRUG DISCOVERY

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

(2019) Aurelien Marabelle et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164

(2019) Dung T. Le et al.   JOURNAL OF CLINICAL ONCOLOGY

1140PDPhase I study of KN035, a novel fusion Anti-PD-L1 antibody administered subcutaneously in patients with advanced solid tumors in the USA

(2018) K P Papadopoulos et al.   ANNALS OF ONCOLOGY

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

(2017) Michael J Overman et al.   LANCET ONCOLOGY

Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer

(2017) Yelena Y. Janjigian et al.   Cancer Discovery

Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade

(2017) Fei Zhang et al.   Cell Discovery

Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers

(2016) Chang Gon Kim et al.   BRITISH JOURNAL OF CANCER

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies

(2014) S. Venderbosch et al.   CLINICAL CANCER RESEARCH

Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer

(2011) Ben Tran et al.   CANCER

Deficient mismatch repair system in patients with sporadic advanced colorectal cancer

(2009) M Koopman et al.   BRITISH JOURNAL OF CANCER